Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00779337




Registration number
NCT00779337
Ethics application status
Date submitted
22/10/2008
Date registered
24/10/2008
Date last updated
22/05/2012

Titles & IDs
Public title
Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas
Scientific title
Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas
Secondary ID [1] 0 0
ANZCTR12608000521325
Secondary ID [2] 0 0
QIMR P1167
Universal Trial Number (UTN)
Trial acronym
EPL
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Lymphoma 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Autologous AdE1- Latent Membrane Protein CTLs

Experimental: Single group study - Autologous AdE1- Latent Membrane Protein (LMP) Cytotoxic T Lymphocytes.


Other interventions: Autologous AdE1- Latent Membrane Protein CTLs
Total dose 20-800 million CTL given in 4 equal doses (5-200 million CTL) given intravenously, at weekly intervals for the first cohort of 10 patients and twice a week for the second cohort of 10 patients.
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Feasibility (generation of autologous clinical grade AdE1-LMP-specific CTL from the blood of EBV-positive lymphoma patients)
Timepoint [1] 0 0
The investigational product for each participant will be assessed post production. The patient will have blood samples taken prior to and following each infusion, and then at 1, 3, 6 & 12 months following the final infusion.
Primary outcome [2] 0 0
Safety as assessed by adverse event monitoring. Patients will be questioned and toxicities recorded according to the International Common Toxicity Criteria.
Timepoint [2] 0 0
1 hour post 4 AdE1-LMP CTL injections (injections are weekly for first 10 participants & twice weekly for the next 10 participants), 3-5 weeks post the 4th injection, then 3, 6 and 12 months post the 4th injection
Primary outcome [3] 0 0
Reconstitution of EBV-specific CTL immunity with anti-viral efficacy measured by immunological & virological assessment of blood samples including immunophenotyping, intracellular cytokine assays, CD107 cytotoxicity assays and EBV DNA load analysis.
Timepoint [3] 0 0
At baseline, pre and 1 hour post 4 AdE1-LMP CTL injections, 3-5 weeks post the 4th injection, then 3, 6 and 12 months post the 4th injection
Secondary outcome [1] 0 0
Optimal dose intensity of the intervention. Clinical efficacy (radiological assessment by CT), biological efficacy (reconstitution of EBV-specific CTL immunity & anti-viral efficacy), safety & efficacy of the 1st treatment schedule vs the 2nd schedule
Timepoint [1] 0 0
Clinical evaluation, AE monitoring & collection of blood samples at baseline, pre & 1 hr post injections, 3-5 weeks, 3, 6 and 12 months post 4th injection. Radiological examination at baseline & at 3 to 5 wks & 3 months post the 4th treatment.
Secondary outcome [2] 0 0
Clinical efficacy
Timepoint [2] 0 0
CT scan +/- additional scans at baseline , 3-5 weeks & 3 months post the 4th injection. Clinical evaluation at baseline, pre and 1 hour post injections, 3-5 weeks, 3, 6 and 12 months post the 4th injection

Eligibility
Key inclusion criteria
- Informed consent.

- EBV-positive lymphoma as determined by in situ hybridization or equivalent (excluding
Burkitts Lymphoma).

- Age 18 years or older.

- ECOG performance status 1, 2 or 3

- Life expectancy of at least 6 months.

- Measurable disease: either relapsing, partially responsive, refractory or progressive
disease, includes disease detected either by clinical examination, radiographic
evaluation (including CT scans, and at physician's discretion by functional imaging),
or a persistently detectable plasma EBV viral load.

- No chemotherapy / radiotherapy and/or antibody therapy for at least 2 weeks prior to
anticipated date of first infusion.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- EBV negative tumour

- Presence of detectable malignant cells in the peripheral circulation by flow cytometry
or morphology

- Serious infection within the past 28 days that has not adequately responded to therapy

- Pregnancy, or unwilling to use adequate contraception

- Serology (taken within 3 months of CTL release date) indicating active HBV or HCV
infection, positive serology for HIV I&II, HTLV1 or syphilis

- Negative serology for EBV

- Psychiatric, addictive or any condition which may compromise the ability to
participate in this trial

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/05/2012
Sample size
Target
Accrual to date
Final
8
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 0 0
Princess Alexandra Hospital - Brisbane
Recruitment postcode(s) [1] 0 0
4102 - Brisbane

Funding & Sponsors
Primary sponsor type
Other
Name
Queensland Institute of Medical Research
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
The Atlantic Philanthropies
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Commercial sector/Industry
Name [2] 0 0
Australian Department of Industry, Tourism and Resources
Address [2] 0 0
Country [2] 0 0
Other collaborator category [3] 0 0
Other
Name [3] 0 0
British Society for Haematology
Address [3] 0 0
Country [3] 0 0
Other collaborator category [4] 0 0
Other
Name [4] 0 0
National Health and Medical Research Council, Australia
Address [4] 0 0
Country [4] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This trial will use a new method of treating lymphoma using a therapy derived from a person's
Killer T cells. These Killer T cells are taken from a person's blood and grown in a test tube
to increase the number of these cells that are specifically active against the lymphoma
cells. The cells are then given to the patient by intravenous infusion with the aim of
killing the lymphoma cells. Potentially this treatment will help to kill the
residual/recurrent tumour that is present after other lymphoma treatment and reduce the
chance of the tumour recurring.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00779337
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Maher K Gandhi, MB CHB PhD
Address 0 0
Queensland Institute of Medical Research
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00779337